Life sciences and healthcare

Industries making an impact on modern society.


Life sciences, health and social care are vitally important in the development of modern society, with a diverse range of stakeholders, from the general public and clinical practitioners to regulators, insurers and governments. We understand the unique challenges of the industry and deliver results-focused advice for a diverse range of clients, from drug developers to healthcare providers and the entities that finance and support them.

Our focus areas


Digital health

Our specialist healthcare technology practice advises the companies and investors that are transforming the way therapies and patient services are delivered.

Learn more

Healthcare

In health and social care, we advise on everything from the building and operating of hospitals and care homes to the provision of new methods of diagnosis and treatment.

Learn more

Life sciences

In life sciences, we have a strong track record in domestic and cross-border mergers and acquisitions, helping our clients to monetise their assets through creative partnering with early-stage entrepreneurial and established companies, and by providing IP and tax advice.

Learn more

Experience


LDC

Advised long-standing client LDC together with the management team on the sale of Penn Pharma in a transaction worth £127m.

Univercells

Advised on a series A investment in Belgian biotech company Univercells.

Telefonica Alpha

Advised Telefonica Alpha (Barcelona) on a software service and the applicability of both healthcare and medical device regulation.

UK telco

Advised a UK telco on regulatory compliance for a range of proposed 'mhealth' services, including whether the services were healthcare services and/or used medical devices.

Healthcare provider

Advised a digital primary care healthcare provider on EU and UK health and data regulations, preparing global contracting documentation and insurance advice.

Intrapharm Laboratories Ltd

Advised Intrapharm Laboratories Ltd management team and all of its shareholders on the disposal of the company to German pharmaceutical company RIEMSER Pharma GmbH.

Drug discovery company

Advised the shareholders of a privately held drug discovery company on its acquisition by C4X Discovery Holdings plc in exchange for shares in C4X.

Roche Diagnostics GmbH

Advised Roche Diagnostics GmbH on the revision of their privacy policy and end-user licence agreements.

Roche Diagnostics GmbH

Advised Roche Diagnostics GmbH on a cloud-based solution for securely hosting critical medical data in compliance with data protection laws in over 30 countries.

Imperial Innovations Group plc

Advised Imperial Innovations Group plc and SV Life Sciences on a £19 million series A investment in Kesios Therapeutics.

First Water

Advised the shareholders of First Water on its acquisition by Scapa Group for consideration of up to £15.3m payable depending on performance in 2016, 2017 and 2018.

Sirigen Group Ltd

Advised medical technology Sirigen Group Ltd on its acquisition by Becton, Dickinson and Company, a leading global medical technology company, for an undisclosed sum.

Takeda Ventures

Advised Takeda Ventures, Inc and Takeda Pharmaceuticals on the investment and formation of a drug discovery collaboration with Heptares Therapeutics Ltd.

3

Fact #20

We advised Grifols on its €5bn acquisition of US company Talecris

Life sciences and healthcare

Insights


Potential infringement of EU Competition Law in the field of pharmaceuticals due to collusive conduct aimed at influencing the use of a medicinal product

Within the framework of a preliminary ruling referred to the Court of Justice of the European Union (“ECJ”) by the Italian Council of State, the Advocate General considered that the

Written on: 25th Oct 2017


Read time 4m

Generic clauses for assignment of employees’ image rights incorporated into employment contracts

In the case in question, it is debated as to whether the inclusion of a generic clause in employment contracts by which the employee expressly consents to the transfer of

Written on: 24th Oct 2017


Read time 2m

HWG aktuell: Einschränkung bei zulassungsbegründenden Studien muss nicht in Werbung erwähnt werden

Werbung für Arzneimittel mit Studienergebnissen muss nicht zwingend offenlegen, dass die Ergebnisse auf einer Post-Hoc-Analyse beruhen. Das hat das Hanseatische Oberlandesgericht entschieden und damit weiter konkretisiert, unter welchen Bedingungen ein

Written on: 17th Oct 2017


Read time 3m

View all insights

Connect with one of our experts


Silvia Steiner's Profile Image

Find your local Life sciences and healthcare experts